Figure 2.

Successful reporter systems combined with molecular imaging are applied in clinical trials. (A) Keu et al. (2017) reported tumor-associated CD8⁺ engineered T lymphocytes expressing both HSV1-tk and interleukin-13 (IL-13) zetakine domain, a chimeric antigen receptor, could be tracked longitudinally by [¹⁸F]FHBG imaging in patients with high-grade glioma [96]. (B) Measles virus and vesicular stomatitis virus expressing hNIS were tested in cancer patients. Assessment of clinical outcomes included [¹⁸F]BF₄⁻ PET or [^99mTc]TcO₄⁻ SPECT imaging.